Biological and mechanical therapies enabled by cardiovas

心血管支持的生物和机械疗法

• 批准号: 6822883
• 负责人: Robert J Lederman
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6822883
• 关键词: angiogenesis; cardiovascular disorder; cardiovascular disorder therapy; drug delivery systems; human subject; human therapy evaluation; image enhancement; magnetic resonance imaging; myocardial infarction; nonhuman therapy evaluation; stem cells; swine

During the past year we have contructed a combined x-ray and MRI interventional suite for clinical and animal research, including a custom image-reconstruction and guidance system. We have demonstrated non-toxic labeling of adult-derived stem cells and serial in-vivo surveillance of injected stem cells into the myocardium of swine using MRI. We have demonstrated direct fluoroscopic MRI targeted delivery of adult-derived stem cells into the borders of myocardial infarctions in swine. We have begun investigation of other interventional MRI applications including aortic aneurysm endograft therapy using fluoroscopic MRI. We have tested the safety of intravascular MRI in human research subjects. Studies are underway to test and develop other novel applications of fluoroscopic MRI, including cardiac valve repair and recanalization of total vascular occlusions. Finally we have begun preparation for two human research trials. One will test the safety and provisional efficacy of parenteral allogeneic adult-derived stem cell therapy for subjects recovering from a myocardial infarction. Another will test the safety and provisional efficacy of novel transcriptional regulatory factor to induce therapeutic angiogenesis, as assessed using MRI.

在过去的一年里，我们构建了一套用于临床和动物研究的X光和MRI联合介入套件，包括定制的图像重建和引导系统。我们已经证明了无毒标记成人来源的干细胞，并使用核磁共振对注射到猪心肌中的干细胞进行了一系列体内监测。我们已经证明了在猪的心肌梗死边缘直接荧光MRI靶向输送成人来源的干细胞。我们已经开始研究其他介入性MRI的应用，包括使用荧光MRI进行主动脉瘤的移植治疗。我们已经在人体研究对象中测试了血管内磁共振的安全性。目前正在进行研究，以测试和开发荧光MRI的其他新应用，包括心脏瓣膜修复和全血管闭塞的再通。最后，我们已经开始为两项人体研究试验做准备。其中一项将测试非肠道同种异体成人来源干细胞疗法对心肌梗塞恢复期受试者的安全性和临时疗效。另一项将测试新的转录调节因子诱导治疗性血管生成的安全性和临时有效性，通过核磁共振进行评估。